<DOC>
	<DOCNO>NCT02018250</DOCNO>
	<brief_summary>This clinical study evaluate escalate dosage MMB4 DMS determine safety deliver intramuscularly ( i.m . ) anterior thigh .</brief_summary>
	<brief_title>Study Evaluate Safety New Oxime , MMB4 DIMETHANESULFONATE ( DMS )</brief_title>
	<detailed_description>The goal study assess safety , tolerability , PK MMB4 DMS EF six cohort choose provide range require PK analysis , include assessment dose proportionality .</detailed_description>
	<mesh_term>Benzyl Alcohol</mesh_term>
	<mesh_term>N , N'-monomethylenebis ( pyridiniumaldoxime )</mesh_term>
	<criteria>Subjects must generally healthy adult male female volunteer , 18to55 yearsof age ; Subjects must physically fit determined physical examination BMI ; Subjects must BMI ≥ 19 ≤ 30 kg/m2 , weight range 5585 kg ; Subjects must adequate venous access ; Females child bear age must pregnant breastfeeding , plan become pregnant duration study , female must negative serum pregnancy test within 28 day treatment , negative serum pregnancy test prior dose ; Females childbearing potential must use adequate contraception , define use hormonal ( oral , injectable , implantable ) barriermethod contraceptive least one month prior drug administration must agree use adequate method contraception least one month follow drug administration . Women lactate exclude . Women without childbearing potential ( undergone total hysterectomy bilateral oophorectomy , history bilateral tubal ligation , two year postmenopausal ) also eligible ; Males must agree use barrier form birth control ( i.e. , condom spermicidal gel ) time checkin clinical unit 30 day exposure study drug ; In opinion Investigator , subject comply protocol likely complete study ; Subjects must provide write informed consent sign date IRBapproved write informed consent screening procedure perform ; Subjects must willing refrain donate blood eight week completion study period ; Subjects must able read/comprehend English ; Subjects nonsmokers/tobacco/nicotine product user within three month first dose must total lifetime exposure cigarettes &lt; 15 packyears . Participation PK study clinical study currently within last 30 day ; History presence significant cardiovascular , hepatic , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease could potentially impact safety subject metabolism drug ; Have active malignancy history metastatic hematologic malignancy exception melanoma situ basal squamous cell carcinoma skin . Subjects must diseasefree ten year ; History glaucoma ; History seizures ; History allergic untoward reaction bispyridinium oximes ; history allergy cotton seed oil history anaphylactic shock ; History chronic pulmonary disease current acute pulmonary disease ; history treatment asthma reactive airway disease past year ; Have ongoing drug abuse/dependence ( include alcohol ) ; recent history ( past five year ) treatment alcohol drug abuse ; current positive urine test drug abuse ; Have consume grapefruit , grapefruit juice , grapefruit containing product , starfruit within seven day prior plan dosing ; Having take , within 14 day plan dosing , prescription nonprescription medication ( include home remedy , herbal supplement nutritional supplement ) unless Principal Investigator/SubInvestigator , consultation Sponsor Medical Monitor , provide statement justify medication take impact result study ( rare exception take prescription drug ground exclusion ) ; Preexistent renal insufficiency ( estimate GFR use GFR prediction equation &lt; 60 mL/min/1.73m^2 , and/or evidence structural functional abnormality ( e.g . PI assessment presence clinically significant hematuria , proteinuria , history abnormality renal image ) and/or abnormal BUN serum creatinine abnormal urinalysis ; Skeletal muscle disease evidence skeletal muscle injury base abnormal ( &gt; 1.5 x ULN ) blood creatine kinase myoglobin level ; Clinically relevant abnormal physical finding ( include vital sign , pulse oximetry , transcutaneous endtidal PCO2 ) laboratory value prestudy period screen assessment could interfere objective study safety subject ; Clinically relevant ECG abnormality base three 12lead ECGs obtain five minute apart ; ECG PR interval ≥ 200 msec screen dosing ; ECG QTc interval &gt; 450 msec male , 470 msec female ( QT interval correct Bazett formula ) ; Supine blood pressure le 100/55 mmHg screen dosing ; Ejection fraction le 55 % screen echocardiogram ; Have spirometry abnormal FEV1 , FVC FEV1/FVC ratio accord current American Thoracic Society/European Respiratory Society standard . Have specify laboratory value ( e.g. , hematology complete blood count differential , serum chemistry urinalysis ) outside normal range age sex deem clinically significant Principal Investigator , within 28 day treatment ; Have positive test hepatitis B surface antigen , hepatitis C , syphilis , human immunodeficiency virus ( HIV ) HIV1 HIV2 ; Have skin condition would interfere injection study drug ; Donated &gt; 480 mL blood last 8 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>